pharmaphorum5y
Mylan’s Lantus biosimilar held up by manufacturing issue
Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second ...
Kiplinger1y
GoodRx Is Offering $35 Insulin Coupons — And You Don't Need Insurance
GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...
Hosted on MSN6mon
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...